Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Iduronate-2-sulphatase protein detection in plasma from mucopolysaccharidosis type II patients.

Molecular genetics and metabolism - 1 Jan 2004

Parkinson Emma J, Muller Viv, Hopwood John J, Brooks Doug A

Abstract excerpt

The lysosomal storage disorder mucopolysaccharidosis type II (MPS II) is caused by a deficiency in the activity of the lysosomal exohydrolase iduronate-2-sulphatase (IDS). MPS II patients present within a spectrum of clinical phenotypes, which reflects the dynamic balance between the level of mutant protein, its residual enzyme activity and the resultant level of storage product. In this study, we have developed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibody Formation
Share to Child
Share to Child, Preschool

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Enzyme Activation

Share to Iduronate Sulfatase

Share to Mucopolysaccharidosis II

Share to Recombinant Proteins

Share to Sensitivity and Specificity

Source

Identifiers

PMID: 14728992
DOI: 10.1016/j.ymgme.2003.11.002

Genes

IDS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Iduronate-2-sulphatase protein detection in plasma from mucopolysaccharidosis type II patients.PMID 14728992Read ↗

Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy.Semantic proximity Read ↗

Analysis of normal and mutant iduronate-2-sulphatase conformation.Semantic proximity Read ↗

Analysis of N-acetylgalactosamine-4-sulfatase protein and kinetics in mucopolysaccharidosis type VI patients.Semantic proximity Read ↗

Mucopolysaccharidosis type II (Hunter syndrome): characterization of the iduronate-2-sulphatase in MPS II skin fibroblasts.Semantic proximity Read ↗

Effect of Anti-Iduronate 2-Sulfatase Antibodies in Patients with Mucopolysaccharidosis Type II Treated with Enzyme Replacement Therapy.Semantic proximity Read ↗

Prediction of neuropathology in mucopolysaccharidosis I patients.Semantic proximity Read ↗

Mucopolysaccharidosis type II--genotype/phenotype aspects.Semantic proximity Read ↗

Prediction of Sanfilippo phenotype severity from immunoquantification of heparan-N-sulfamidase in cultured fibroblasts from mucopolysaccharidosis type IIIA patients.Semantic proximity Read ↗

Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II.Semantic proximity Read ↗

Assessment of iduronate-2-sulfatase mRNA expression in Hunter syndrome (mucopolysaccharidosis type II).Semantic proximity Read ↗

Genotype-phenotype correlations in mucopolysaccharidosis type I using enzyme kinetics, immunoquantification and in vitro turnover studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.